Top 5 Hidden PBM Fees Employers Miss

Why Hidden PBM Fees Deserve a Closer Look

Most employers know pharmacy benefits are expensive. Fewer can see exactly where the money goes after a prescription claim is processed, a rebate is reconciled, or a specialty drug is routed through the plan. That gap between visible cost and actual cost is where hidden PBM fees can quietly affect the total performance of a pharmacy benefit program.

The issue is not that every fee is improper. PBMs perform real administrative, clinical, network, and claims functions. The problem is that fee structures are often difficult to trace, compare, and audit. An employer may believe it is evaluating a low-cost PBM arrangement based on headline discounts, rebate guarantees, or administrative fees, while other charges, retained economics, and pricing spreads continue to shape the plan’s true net cost.

That is why PBM transparency is moving from a benefits topic to a business governance topic. In January 2026, the U.S. Department of Labor proposed new PBM fee disclosure rules for self-insured group health plans, noting that plan fiduciaries often cannot obtain full visibility into payments PBMs and affiliates receive from manufacturers, pharmacies, and others. The proposed rule specifically highlights manufacturer rebates, spread-type compensation, and pharmacy recoupments as areas where disclosure matters.

For employers, the takeaway is straightforward: pharmacy cost control starts with knowing which dollars are visible, which dollars are retained elsewhere, and which dollars are hard to verify. A PBM contract may look competitive on the surface and still leave room for unexpected cost through spread pricing, specialty markups, rebate retention, implementation charges, and dispensing spreads.

Key Takeaways

• Hidden PBM fees are not always labeled as fees. They may appear as pricing spreads, retained rebates, specialty pharmacy economics, implementation charges, or dispensing-related differences between what the plan pays and what pharmacies receive.
• Employers should evaluate total net cost, not only rebate guarantees, AWP discounts, or administrative fee schedules.
• Specialty drug claims deserve close review because high-dollar claims can magnify small pricing differences and may involve affiliated specialty pharmacy arrangements.
• The most useful PBM reporting connects claim-level data, rebate detail, pharmacy reimbursement, plan payment, member cost share, and contract terms in a way the employer can audit.
• A transparent, pass-through model helps employers replace assumptions with evidence and make more defensible pharmacy benefit decisions.

What Are Hidden PBM Fees?

Hidden PBM fees are costs, retained payments, pricing differences, or contract charges that are not obvious when an employer reviews only the headline PBM proposal. They may be permitted by contract, but still affect the employer’s true net pharmacy cost if they are not clearly disclosed, passed through, or reconciled.

In practical terms, a hidden fee is any PBM-related economic arrangement an employer cannot easily answer with claim-level evidence: What did the plan pay? What did the pharmacy receive? What rebate or other remuneration was collected? What was retained? What administrative, clinical, network, or implementation charge applied?

Why Employers Miss These Fees

Employers miss PBM fees for a simple reason: pharmacy benefit contracts often use different measurements for different parts of the transaction. One section may focus on average wholesale price discounts. Another may address dispensing fees. Another may describe rebates, guarantees, audit rights, exclusions, reconciliation timing, specialty pharmacy terms, or administrative charges. Each item may look reasonable in isolation.

The financial impact appears when those items interact. A high rebate can mask a higher gross drug cost. A low administrative fee can be offset by retained spread. A strong network discount can be less meaningful if specialty drugs are marked up through an affiliated pharmacy channel. A clean implementation budget can change when file feeds, eligibility issues, formulary mapping, or custom reporting create additional fees.

Employers do not need to become pharmacy pricing technicians. But they do need a disciplined review process that asks the same question repeatedly: does this term reduce total net cost, or does it simply move cost to a place that is harder to see?

1. Spread Pricing

What It Is

Spread pricing occurs when the PBM charges the plan one amount for a prescription drug claim, reimburses the dispensing pharmacy a lower amount, and retains the difference. The spread may not show up as an administrative fee, which is why employers can miss it when they focus only on per-claim fees or discount guarantees.

Spread pricing has received significant public and policy attention because it can make pharmacy benefit costs difficult to verify. The Congressional Budget Office, in its discussion of federal PBM reform proposals, described spread pricing as the difference PBMs retain between what is paid to a pharmacy and what is charged to a health plan or patient. KFF similarly notes that spread pricing can raise costs for insurers while putting reimbursement pressure on pharmacies.

Why It Matters

Spread pricing creates a conflict between the employer’s need for lowest net cost and the PBM’s ability to retain margin inside the claim transaction. If the PBM earns more when the spread is larger, the employer may not have full confidence that the price it pays reflects the pharmacy’s reimbursement plus a clearly defined service fee.

This does not mean every spread arrangement produces the same outcome. But it does mean employers should know whether spread pricing is allowed, how it is measured, whether it applies to all claims or only certain channels, and whether claim-level reporting lets the plan compare plan-paid amounts to pharmacy reimbursement.

What Employers Should Ask

• Does the contract prohibit spread pricing across retail, mail, and specialty claims?
• Will the PBM disclose pharmacy reimbursement at the claim level?
• Are administrative fees fixed and transparent, or can margin be earned inside the drug price?
• Are there exclusions, definitions, or reconciliation rules that allow spread economics to remain in place?

2. Specialty Markups

What It Is

Specialty markups occur when high-cost specialty drugs are priced to the plan at amounts that exceed a transparent acquisition-cost benchmark, pharmacy reimbursement amount, or contractually expected price. The issue is especially important when the PBM owns or is affiliated with the specialty pharmacy dispensing the drug.

Specialty claims are a natural focal point because they are high-dollar, clinically complex, and often concentrated among a smaller number of members. Even a modest percentage difference on a specialty claim can have a meaningful budget impact. In its January 2025 second interim staff report, the Federal Trade Commission reported that the largest PBMs imposed substantial markups on numerous specialty generic drugs dispensed through affiliated pharmacies and identified billions of dollars in dispensing revenue above estimated acquisition cost over the study period.

Why It Matters

Employers often evaluate specialty management based on access, utilization controls, prior authorization, clinical review, and patient support. Those elements matter. But financial oversight matters just as much. A plan can have strong utilization management and still overpay if specialty pricing, pharmacy channel requirements, or affiliated-pharmacy reimbursement are not transparent.

Specialty markups also complicate rebate analysis. A specialty drug may produce a rebate, but the employer still needs to know whether the net cost after rebate is better than a lower-cost therapeutic alternative, a different sourcing pathway, or a more transparent specialty arrangement.

What Employers Should Ask

• Which specialty pharmacies may dispense under the plan, and are any affiliated with the PBM?
• How are specialty drug prices set, and what benchmarks or acquisition-cost references are used?
• Can the employer audit specialty claims, including plan-paid amounts, pharmacy reimbursement, member cost share, and rebates?
• Does the PBM report specialty trend separately from non-specialty trend, with enough detail to identify the top cost drivers?

3. Rebate Retention

What It Is

Rebate retention occurs when a PBM keeps some portion of manufacturer rebates, administrative fees, price protection payments, data fees, or other remuneration tied to drug utilization instead of passing the full value back to the plan. Sometimes the contract promises a guaranteed rebate amount but does not provide full visibility into what was actually collected.

Rebates are not automatically bad. They can reduce plan cost when they are fully passed through and evaluated against the drug’s total net cost. The problem arises when rebate economics create a misleading picture. A high-rebate drug may still cost more than a clinically appropriate lower-rebate alternative. A rebate guarantee may look attractive while other forms of manufacturer compensation are excluded from pass-through language.

Why It Matters

Employers should be cautious about evaluating PBM performance by rebate size alone. The more important question is whether the plan is achieving the lowest defensible net cost after all payments, discounts, fees, and member impact are considered.

KFF notes that PBMs may retain a portion of negotiated rebates, particularly in the commercial employer market, and that rebate incentives may favor higher-priced drugs with higher rebates over lower-priced drugs with low or no rebates. For employers, that is a reminder to look beyond rebate checks and ask whether the formulary strategy is aligned with total plan cost.

What Employers Should Ask

• Are 100% of rebates and other manufacturer payments passed through to the plan?
• How does the contract define rebate, administrative fee, service fee, price protection, data fee, and other remuneration?
• Can the employer reconcile invoiced claims to rebate payments at the NDC or claim level?
• Does the PBM prioritize true lowest net cost over rebate maximization when formulary decisions are made?

4. Implementation Fees

What It Is

Implementation fees are charges tied to onboarding a new pharmacy benefit program. They may include eligibility file setup, custom accumulators, plan design configuration, formulary mapping, data feeds, member materials, ID card coordination, reporting setup, vendor integrations, testing, or project management.

Unlike spread pricing or rebate retention, implementation fees are usually easier to identify when they are listed clearly. Employers miss them when they are scattered across statements of work, change orders, setup schedules, custom reporting agreements, or post-sale operational requests.

Why It Matters

A smooth implementation has real value. Poor implementation can create member disruption, claim rejects, inaccurate accumulators, delayed reporting, and avoidable HR burden. The goal is not to avoid every implementation cost. The goal is to know which services are included, which are extra, and how the PBM will handle the inevitable changes that occur between contract signing and go-live.

Implementation fees also affect apples-to-apples PBM comparisons. One proposal may include broader setup support in the base fee. Another may show a lower headline price while charging separately for items the employer assumed were standard. Without a clear implementation scope, the lower-cost proposal may not be lower in practice.

What Employers Should Ask

• What implementation services are included in the base arrangement?
• Which items trigger additional fees, such as custom files, reporting, plan changes, or accelerated timelines?
• Are post-go-live fixes included when issues relate to setup or vendor coordination?
• Will the PBM provide a detailed implementation workplan with owners, deadlines, dependencies, and escalation paths?

5. Dispensing Spreads

What It Is

Dispensing spreads are differences tied to the dispensing side of the claim, including dispensing fees charged to the plan, reimbursement paid to the pharmacy, network rates, mail or specialty channel economics, and any pharmacy recoupments or adjustments. These can overlap with spread pricing, but they deserve separate attention because employers often review ingredient cost more closely than dispensing economics.

The Department of Labor’s 2026 proposed disclosure rule specifically called out compensation received when the plan-paid drug price exceeds the amount reimbursed to the pharmacy, as well as payments recouped from pharmacies in connection with prescriptions dispensed to the plan. That framing matters because dispensing economics can be hidden in the space between plan payment, pharmacy reimbursement, and later adjustments.

Why It Matters

Dispensing economics affect both plan cost and pharmacy access. If reimbursement is too low, community pharmacies may struggle to participate sustainably. If plan charges are too high, the employer may overpay. If recoupments and adjustments are not visible, the employer may not understand the true economics of the network it is funding.

This is especially relevant for employers that value broad community pharmacy access. A transparent model should help the employer understand what the plan pays, what pharmacies receive, what fees apply, and how those economics support member access without creating unnecessary plan cost.

What Employers Should Ask

• What dispensing fee does the plan pay by channel, and what does the pharmacy receive?
• Are direct and indirect remuneration, audit recoupments, performance fees, or network adjustments disclosed?
• Do mail, retail, and specialty channels use different reimbursement or fee structures?
• Can the employer evaluate pharmacy network performance without losing sight of patient access and plan cost?

How to Review PBM Fees Before Renewal

The best time to uncover PBM fees is before renewal or RFP decisions are finalized. Employers should ask for contract language, data access, reporting samples, and audit rights early enough to compare models on total net cost rather than surface-level guarantees.

A practical review should include five steps.

1. Map every revenue source. Ask the PBM to identify all sources of compensation, including administrative fees, spread, rebates, manufacturer payments, pharmacy network payments, data fees, implementation charges, clinical program fees, and affiliate revenue.
2. Require claim-level transparency. Summary reports are helpful, but they rarely show enough detail. Employers need the ability to connect plan-paid amounts, member cost share, pharmacy reimbursement, rebate eligibility, and final net cost.
3. Review definitions, not just promises. Words like pass-through, transparent, rebate, specialty, spread, and generic effective rate can vary by contract. Definitions determine whether the promise is enforceable.
4. Separate gross savings from net savings. A large discount or rebate does not automatically mean the plan paid less. The review should compare alternatives based on total plan impact.
5. Preserve audit rights. Employers should be able to verify that contract terms match actual claim and payment activity. Auditability is what turns transparency from a statement into a control.

Where MaxCare Rx Fits

MaxCare Rx is built around a different pharmacy benefit conversation: true lowest net cost, transparent pass-through pricing, zero spread pricing, clinical oversight, and actionable reporting. For employers, brokers, consultants, and TPAs, that means the focus shifts from chasing the largest rebate or the most attractive headline discount to understanding what is actually driving total pharmacy spend.

That distinction matters. Employers do not need more pharmacy data for its own sake. They need financial clarity they can use: which drugs are driving trend, which contract terms affect net cost, which specialty claims need closer management, and which plan design decisions can reduce unnecessary spend while maintaining appropriate member access.

A transparent PBM model also makes broker and TPA conversations easier. When the economics are clear, advisors can explain recommendations with more confidence. CFOs can evaluate pharmacy benefits as a financial strategy. HR leaders can support employees without being trapped between rising cost and unclear vendor answers.

Conclusion: Hidden Fees Are a Signal to Demand Better Visibility

Hidden PBM fees are not just a contract issue. They are a plan performance issue. Spread pricing, specialty markups, rebate retention, implementation fees, and dispensing spreads can all change the economics of a pharmacy benefit program, especially when employers cannot verify the details behind the invoice.

The solution is not to assume every PBM arrangement is misaligned. The solution is to insist on clarity. Employers should know how their PBM is paid, how claims are priced, how rebates are handled, how specialty drugs are managed, and how every meaningful cost can be audited.

MaxCare Rx helps employers and their advisors evaluate pharmacy benefits through that lens: transparent pricing, disciplined financial oversight, clinically responsible cost management, and reporting that turns complexity into action. If your organization is preparing for renewal, reviewing PBM proposals, or trying to understand why pharmacy spend keeps rising, start with the five fee categories above. They will tell you whether your current arrangement is built for visibility or whether important dollars are still sitting out of view.

FAQ

What is the most common hidden PBM fee employers miss?

Spread pricing is one of the most commonly discussed hidden PBM economics because it can be retained inside the claim rather than shown as a separate fee. Employers should also review rebate retention and specialty pharmacy pricing because those areas can materially affect total net cost.

Are PBM rebates bad for employers?

Not necessarily. Rebates can reduce plan cost when they are fully passed through and evaluated against the total cost of the drug. The risk is relying on rebate size as the main measure of savings while missing lower-net-cost alternatives or retained manufacturer payments.

How can an employer tell if a PBM uses spread pricing?

The employer should review the contract definition of spread pricing, request claim-level reporting that shows plan-paid amounts and pharmacy reimbursement, and confirm whether spread pricing is prohibited across retail, mail, and specialty channels.

Why are specialty drugs a major PBM fee risk?

Specialty drugs often have high claim costs, complex clinical requirements, and channel-specific dispensing arrangements. When the PBM or an affiliate owns the specialty pharmacy, employers should request clear pricing, reimbursement, rebate, and audit detail.

What should employers ask during a PBM RFP?

Employers should ask for all PBM revenue sources, rebate pass-through terms, spread pricing prohibitions, specialty pricing methodology, implementation fee schedules, sample claim-level reports, audit rights, and definitions for every major financial term.

What does true lowest net cost mean in pharmacy benefits?

True lowest net cost means evaluating the total financial impact after drug price, discounts, rebates, fees, member cost share, utilization controls, and clinical appropriateness are considered. It is broader than chasing the largest rebate or deepest discount percentage.

How often should employers audit PBM fees?

Employers should review PBM economics before each renewal or RFP and preserve audit rights for ongoing verification. A mid-year review can also help identify trend drivers before renewal decisions are already locked in.